Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
eBioMedicine is Scopus-indexed (Q1, CiteScore 19.1), WoS SCIE, DOAJ. It is covered by India's One Nation One Subscription scheme, which pays the article processing charge for authors at eligible institutions. Published by Elsevier B.V..
Checked against the index lists dated .
ISSN 2352-3964Verify ISSN ↗
Publisher: Elsevier B.V.
Cost to publish: APC covered for authors at ONOS-subscribed Indian institutions
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Medicine (all) | 13 / 669 | 98th | Q1 |
| Biochemistry, Genetics and Molecular Biology (all) | 11 / 223 | 95th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription)
Yes — actively indexed in Scopus, coverage 2014–present, best quartile Q1, CiteScore 19.1.
eBioMedicine is Q1 in Medicine (all) (rank 13 of 669) and Q1 in Biochemistry, Genetics and Molecular Biology (all) (rank 11 of 223), by CiteScore 2025.
eBioMedicine is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 19.1, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.742, quartile Q1, with an H-index of 156.
For authors at Indian institutions covered by One Nation One Subscription (ONOS), the article processing charge is paid by the scheme. The publisher lists an article processing charge of about US$5,780 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
eBioMedicine is published by Elsevier B.V. Its ISSN is 2352-3964.
Yes. ONOS also covers its article processing charge for authors at eligible institutions.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
eBioMedicine has an h-index of 185 and a 2-year mean of 10.34 citations per paper (OpenAlex). Its Scopus CiteScore is 19.1, quartile Q1. On 2-year citations it ranks #16 of 646 Scopus journals in Medicine (all).
eBioMedicine published 548 papers in 2025; its busiest recent year was 2019 with 727. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2026), authors are most often from United States (20.1%), China (19.4%) and United Kingdom (8.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 21 retracted papers are recorded (3.3 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.